EN
EN
BioNova Announces Submission of Investigational New Drug for BN102 for the Treatment of Hematologic Malignancies in China
January 05, 2022

BioNova today announced that it has submitted an investigational new drug (IND) application for BN102 for the treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-cell Non-Hodgkin Lymphoma (NHL) to the China National Medical Products Administration (NMPA).